Baidu
map

Nature Communications:对老鼠的实验证明二甲双胍能延年益寿

2013-08-01 koo bio360

注射低剂量的美弗明能延长白鼠寿命 最新一期科学杂志《自然通讯》上刊登的一项研究结果显示,治疗糖尿病的药二甲双胍(也称美福明)能延长雄性老鼠的寿命。 科学家认为,二甲双胍也许具有类似极端热量限制法的效果,该方法是严格限制饮食中的卡路里量的摄入,据认为有助于健康长寿。 美国马里兰州巴尔的摩国家老龄问题研究所的拉斐尔·卡布博士说,对动物所作的实验室研究证明,限制热量摄入能延长寿命。 拉斐尔·卡布


注射低剂量的美弗明能延长白鼠寿命

最新一期科学杂志《自然通讯》上刊登的一项研究结果显示,治疗糖尿病的药二甲双胍(也称美福明)能延长雄性老鼠的寿命。

科学家认为,二甲双胍也许具有类似极端热量限制法的效果,该方法是严格限制饮食中的卡路里量的摄入,据认为有助于健康长寿。

美国马里兰州巴尔的摩国家老龄问题研究所的拉斐尔·卡布博士说,对动物所作的实验室研究证明,限制热量摄入能延长寿命。

拉斐尔·卡布和他的小组正在研究,是否用药物限制热量的摄入,也能起到同样的效果。

二甲双胍是2型糖尿病人最广泛使用的处方药,2型糖尿病主要发生在40岁以上的人群中。

它也用来治疗代谢综合症,那是一种糖尿病、高血压和肥胖症的组合病症。
过去所作的实验结果显示,二甲双胍可以延长蠕虫之类的简单有机体的寿命,但是在对苍蝇和哺乳动物身上所作的实验结果却不相同。

研究结果令人鼓舞

拉斐尔·卡布的小组给中年雄性老鼠使用不同剂量的二甲双胍后,发现低剂量二甲双胍不仅延长了老鼠5%的寿命,而且延缓了与年龄相关疾病的发病时间。
但是使用高剂量二甲双胍却有害,会缩短老鼠的生命。

卡布博士说,目前还不清楚,是否使用低剂量二甲双胍对人类也能起到能延长寿命的效果,所以还需要作更多研究和临床实验。

他还说,这一研究结果很令人鼓舞,至少可以证明,良好的饮食习惯和锻炼肯定对健康和长寿有帮助。

英国纽卡瑟尔大学教授汤姆·柯克伍德说,二甲双胍是一种有效控制代谢的治疗2型糖尿病的药物。

而长久以来医学界都知道,控制老鼠的代谢,能延长它们的生命,并推迟与年龄相关疾病的发生。

但是目前还不清楚的是,二甲双胍在老鼠身上起到的作用,是否在人类身上也同样会发生。

Alejandro Martin-Montalvo, Evi M. Mercken, Sarah J. Mitchell, Hector H. Palacios, Patricia L. Mote, Morten Scheibye-Knudsen, Ana P. Gomes, Theresa M. Ward, Robin K. Minor, Marie-José Blouin, Matthias Schwab, Michael Pollak, Yongqing Zhang, Yinbing Yu, Kevin G. Becker, Vilhelm A. Bohr, Donald K. Ingram, David A. Sinclair, Norman S. Wolf, Stephen R. Spindler, Michel Bernier & Rafael de Cabo. Metformin improves healthspan and lifespan in mice. Nature Communications, 30 July 2013; doi:10.1038/ncomms3192

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]
    2013-12-06 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]
    2013-10-09 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]
    2013-08-09 lxm5668

    期待

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1797861, encodeId=e9c91e978614a, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Oct 17 04:14:00 CST 2013, time=2013-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086640, encodeId=c45c208664069, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Dec 06 19:14:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879604, encodeId=02e318e96046a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 09 13:14:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6045, encodeId=7a1a604538, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e52e84884, createdName=lxm5668, createdTime=Fri Aug 09 17:53:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951395, encodeId=130819513959e, content=<a href='/topic/show?id=637349503a9' target=_blank style='color:#2F92EE;'>#延年益寿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49503, encryptionId=637349503a9, topicName=延年益寿)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Dec 24 04:14:00 CST 2013, time=2013-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573385, encodeId=020a15e338577, content=<a href='/topic/show?id=28f4125430b' target=_blank style='color:#2F92EE;'>#Nature Communications#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12543, encryptionId=28f4125430b, topicName=Nature Communications)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bea15872676, createdName=qindq, createdTime=Sat Aug 03 02:14:00 CST 2013, time=2013-08-03, status=1, ipAttribution=)]

相关资讯

ADA2013:阿格列汀与二甲双胍联用治疗糖尿病效果好

  一项名为ENSURE(比较阿格列汀与格列吡嗪在与二甲双胍联用两年的疗效与安全性的持久性试验)的研究,近日在第73届美国糖尿病学会年会(ADA)上发布。   该研究历时2年,旨在获得有关阿格列汀在治疗II型糖尿病患者的疗效和安全性方面的新数据。ENDURE研究是一项多中心的随机双盲活性对照研究,由日本武田药品工业株式会社组织多国专家开展,用以评估阿格列汀和格列吡嗪在与二甲双胍联用时,其

含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗

  胰岛素抵抗及进行性β细胞衰竭是2型糖尿病进展的主要原因。ADA和欧洲糖尿病研究学会(EASD)推荐,在避免发生低血糖的前提下,应尽可能将患者HbA1c降至正常水平。然而,之前并无研究探讨其最佳治疗方案。  美国田纳西大学圣安东尼奥健康医学中心阿卜杜勒-加尼(Abdul-Ghani)等认为,对新诊断2型糖尿病患者,目前推荐的以二甲双胍序贯递加磺脲类及基础胰岛素治疗仅着眼于降低血糖,

社区中使用二甲双胍在糖尿病治疗中的应用1例

  糖尿病是目前社区卫生服务中心全科医师主要接触和管理的慢性病之一。只有社区全科医师与患者通力合作,加强血糖监测和控制,才能预防和延缓糖尿病并发症的发生。该文是1位社区全科医师在进行糖尿病患者管理过程中的感悟,让我们一同分享。   病例简介   现病史   患者李某,2011年1月于我院就诊。   患者患有2型糖尿病13年,原服药无规律,现服用二甲双胍500 mg,每日3

JCEM:安体舒通与二甲双胍联合治疗PCOS优于单独用药

为了改善多囊卵巢综合症(PCOS)女性的治疗结局,多种药物如格列酮类、口服避孕药和抗雄激素类药物常与二甲双胍联合使用。为了比较在PCOS女性治疗中,小剂量安体舒通和二甲双胍联合用药与任一药物单用的疗效,来自印度克什米尔大学的Mohd Ashraf Ganie教授及其团队进行了一项研究,该研究发现在PCOS女性,小剂量安体舒通与二甲双胍联合用药在临床获益和依从性方面似乎优于任何一个单独用药。该研究结

ADA 2013:ORIGIN研究揭示甘精胰岛素和二甲双胍不改变癌症发生风险

几项对理赔数据库的回顾性分析发现,胰岛素使用与癌症发生(CA)有关,二甲双胍可减少癌症发生。Louise Bordeleau博士在美国糖尿病学会2013年会上介绍了ORIGIN的研究结果,发现二甲双胍和甘精胰岛素对受试者的CA风险没有影响。 ORIGIN研究是一项国际性双盲随机2*2析因试验,对比在心血管(CV)风险较高的糖尿病前期或糖尿病(DM)患者中,甘精胰岛素(来得时)或标准治疗与omeg

ADA:两药联用可增加糖尿病疗效

  一项名为ENSURE(比较阿格列汀与格列吡嗪在与二甲双胍联用两年的疗效与安全性的持久性试验)的研究,近日在第73届美国糖尿病学会年会(ADA)上发布。   该研究历时2年,旨在获得有关阿格列汀在治疗II型糖尿病患者的疗效和安全性方面的新数据。ENDURE研究是一项多中心的随机双盲活性对照研究,由日本武田药品工业株式会社组织多国专家开展,用以评估阿格列汀和格列吡嗪在与二甲双胍联用时,其

Baidu
map
Baidu
map
Baidu
map